ANTI-AGEING 19


Figure 13: In vivo study: 2D images.


reported in Figure 12. The in vivo topical treatment in 18 volunteers during 56 days with Targeted Q10 displays anti-ageing effects, through significant increase of skin firmness by 10% and elasticity by 14 %, in higher levels than treatment with Free Q10. It is interesting to note also that we achieved these results in 28 days, which is not possible to achieve with free Q10. It is worth pointing out that in the case of targeted Q10 we are working with an amount of Q10 3000 times lower than in the case of free Q10. In Figure 13, we have reported the 2D images of the area selected (ROI) and its topography, by the curvature analysis from that selected area. The total area, length and depth are obtained from the 3D reconstructions (in pixels). We can appreciate a significant reduction of fine lines in the case of Targeted Q10 application and in particular, we observe a 25% reduction of lines area and length, while with the free Q10 we basically do not see any improvement of the fine lines.


Conclusion To sum up, Trojan Q10 changes the game in the delivery of active ingredients to the mitochondria, and in particular in the delivery of Q10. In fact, Trojan Q10 displays:


l Enhanced penetration in skin l Selectivity to fibroblast mitochondria and release of Q10 into mitochondria


l Protective and re-energise action on fibroblasts, by restoring optimal mitochondrial activity and neutralising reactive oxygen species (ROS)


September 2020 Table 1: Comparison between Free Q10 and Trojan Q10. Free Q10 Solubility


Penetration Mechanism


Activity ROS Neutralization ATP Production


Age-related cell processes activation (ECM proteins synthesis, fibroblast turnover...)


Level of use (of Q10)


Visible results on skin (Skin Firmness - Elasticy - AntiWrinkles)


Oil soluble


Slow-low penetration (epidermal) General. Unspecific


Overall free radical scavenger / Antioxidant


General. Unspecific. Minimum at mitochondria


Lowest (Q10 consumed before reaching mito)


Lowest (Q10 consumed before reaching mito)


0.1-1.0% Mid-Long term


l Increased synthesis of Collagen IV and VII Increased skin firmness and elasticity The critical difference between Free Q10


and Trojan Q10 is the ability of Trojan Q10 to effectively deliver Q10 in correspondence of the mitochondria. This unlocks unexploited features of conventional Q10 treatments: when Q10 reaches the mitochondria, it can participate to the mitochondria respiration, i.e. energy production, and it can neutralise mROS. Only by mastering these two actions of Q10, a Q10-based treatment can achieve unexpected anti-wrinkles effect in a short time and at a low dose of Q10 (0.00003%- 0.0003%). In fact, in the case of Trojan Q10,


Water dispersible Fast-Deep penetration (dermal)


Targeted. Specific. Mitochondrial functions.


Energy production/ROS control at mitochondria level


Sp[ecific inside the mitochondria: ROS production source


Highest (mitochondrial activity. Targeted Q10)


Highest (mitochondrial activity. Targeted Q10)


0.00003% - 0.0003% Short-Mid term


all the wrinkles-related cellular processes, such as ECM proteins synthesis, fibroblasts turnover, etc are speeded up as well as mROS damage is minimised, leading to an increase in skin firmness and elasticity in a short time. Free Q10, even at higher doses (0.3%-1%) cannot achieve these results because it is consumed before reaching the mitochondria; it acts on skin mainly as anti- oxidant, neutralising ROS and avoiding the related damage. So, in order to achieve significant anti-wrinkles effect by Free Q10, constant and long-term treatments are needed (6-8 months). In Table 1, the main differences between Free Q10 and Trojan Q10 are summarised.


PC PERSONAL CARE EUROPE


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92